Conclusion
It has always seemed physiologically perverse that evolution should have permitted the development of what is termed vitamin K deficiency in normal term infants who are breast fed, resulting in a small but definable risk of haemorrhagic disease of the newborn. The most likely explanation for this situation is that there is some evolutionary advantage that outweighs this risk. The finding of an increased incidence of childhood cancer in children given intramuscular vitamin K in the neonatal period suggests that a relative deficiency in vitamin K during this critical phase of rapid growth and development may protect vulnerable tissues from mutagenesis. The protection afforded by oral vitamin K against haemorrhagic disease does not appear to carry the same risk of inducing malignancy, so it may be prudent to use oral rather than intramuscular vitamin K.
We placebo (p<OO 1). This effect was shown quantitatively by a striking reduction in symptoms of the premenstrual syndrome measured with the premenstrual assessment form (figure). Analysis of variance showed that the superiority of fluoxetine did not depend on whether it was given before or after placebo (F,1 4= 175; NS).
The onset of action of fluoxetine was variable, seven of the 16 women showing improvement two weeks after initiation and eight responding after a further four to eight weeks. Prompt relapse of the premenstrual syndrome was observed 18-25 days after stopping fluoxetine in seven of nine women who crossed over to placebo, four rating their premenstrual syndrome as distinctly worse than usual. In women who chose to continue or resume fluoxetine after breaking the code efficacy was being maintained up to 12 months later.
Comment
Fluoxetine was an effective treatment for the severe premenstrual symptoms experienced by our sample, in 12 of 16 cases exceeding the effect of placebo. Patient enthusiasm for fluoxetine was clear, particularly among the eight women achieving full remission of symptoms. Several women expressed delight at feeling "normal" throughout their cycle, a view supported by the finding that while taking fluoxetine the premenstrual syndrome group had symptom scores comparable to those of a control sample (figure). The efficacy of fluoxetine in severe premenstrual syndrome was consistent with findings of other recent studies of serotoninergic agents, including buspirone, clomipramine, fenfluramine, and fluoxetine. 
